47 related articles for article (PubMed ID: 8974649)
1. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function.
Romero J; de Miguel R; García-Palomero E; Fernández-Ruiz JJ; Ramos JA
Brain Res; 1995 Oct; 694(1-2):223-32. PubMed ID: 8974649
[TBL] [Abstract][Full Text] [Related]
2. The effect of anandamide on prolactin secretion is modulated by estrogen.
Scorticati C; Mohn C; De Laurentiis A; Vissio P; Fernández Solari J; Seilicovich A; McCann SM; Rettori V
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2134-9. PubMed ID: 12578974
[TBL] [Abstract][Full Text] [Related]
3. Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats.
Morera-Herreras T; Ruiz-Ortega JA; Linazasoro G; Ugedo L
Psychopharmacology (Berl); 2011 Mar; 214(2):379-89. PubMed ID: 20959968
[TBL] [Abstract][Full Text] [Related]
4. Novel, potent THC/anandamide (hybrid) analogs.
Bourne C; Roy S; Wiley JL; Martin BR; Thomas BF; Mahadevan A; Razdan RK
Bioorg Med Chem; 2007 Dec; 15(24):7850-64. PubMed ID: 17827022
[TBL] [Abstract][Full Text] [Related]
5. Anandamide Attenuates Neurobehavioral Deficits and EEG Irregularities in the Chronic Sleep Deprivation Rats: The Role of Oxidative Stress and Neuroinflammation.
Belali R; Mard SA; Khoshnam SE; Bavarsad K; Sarkaki A; Farbood Y
Neurochem Res; 2024 Jun; 49(6):1541-1555. PubMed ID: 37966567
[TBL] [Abstract][Full Text] [Related]
6. Δ
McIntosh AL; Martin GG; Huang H; Landrock D; Kier AB; Schroeder F
J Lipid Res; 2018 Apr; 59(4):646-657. PubMed ID: 29414765
[TBL] [Abstract][Full Text] [Related]
7. Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity.
Chetia S; Borah G
Nat Prod Bioprospect; 2020 Oct; 10(5):285-296. PubMed ID: 32860199
[TBL] [Abstract][Full Text] [Related]
8. Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.
Babayeva M; Assefa H; Basu P; Chumki S; Loewy Z
Parkinsons Dis; 2016; 2016():1279042. PubMed ID: 28050308
[TBL] [Abstract][Full Text] [Related]
9. The effects of Δ
Bloomfield MA; Ashok AH; Volkow ND; Howes OD
Nature; 2016 Nov; 539(7629):369-377. PubMed ID: 27853201
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine.
Moghaddam HF; Khodayar MJ; Abarghouei SM; Ardestani MS
Saudi Pharm J; 2010 Oct; 18(4):207-15. PubMed ID: 23960729
[TBL] [Abstract][Full Text] [Related]
11. The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms.
Bosier B; Muccioli GG; Lambert DM
Br J Pharmacol; 2013 Jun; 169(4):794-807. PubMed ID: 22970888
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors.
Hayase T
BMC Pharmacol; 2011 Jul; 11():6. PubMed ID: 21767384
[TBL] [Abstract][Full Text] [Related]
13. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.
Kurz A; Double KL; Lastres-Becker I; Tozzi A; Tantucci M; Bockhart V; Bonin M; García-Arencibia M; Nuber S; Schlaudraff F; Liss B; Fernández-Ruiz J; Gerlach M; Wüllner U; Lüddens H; Calabresi P; Auburger G; Gispert S
PLoS One; 2010 Jul; 5(7):e11464. PubMed ID: 20628651
[TBL] [Abstract][Full Text] [Related]
14. The endocannabinoid system as a target for the treatment of motor dysfunction.
Fernández-Ruiz J
Br J Pharmacol; 2009 Apr; 156(7):1029-40. PubMed ID: 19220290
[TBL] [Abstract][Full Text] [Related]
15. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs.
Hayase T
BMC Neurosci; 2007 Sep; 8():76. PubMed ID: 17877812
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid system as an emerging target of pharmacotherapy.
Pacher P; Bátkai S; Kunos G
Pharmacol Rev; 2006 Sep; 58(3):389-462. PubMed ID: 16968947
[TBL] [Abstract][Full Text] [Related]
17. Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens.
Pickel VM; Chan J; Kearn CS; Mackie K
J Comp Neurol; 2006 Mar; 495(3):299-313. PubMed ID: 16440297
[TBL] [Abstract][Full Text] [Related]
18. Endocannabinoids and exercise.
Dietrich A; McDaniel WF
Br J Sports Med; 2004 Oct; 38(5):536-41. PubMed ID: 15388533
[TBL] [Abstract][Full Text] [Related]
19. Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse.
González S; Valenti M; de Miguel R; Fezza F; Fernández-Ruiz J; Di Marzo V; Ramos JA
Br J Pharmacol; 2004 Oct; 143(4):455-64. PubMed ID: 15371286
[TBL] [Abstract][Full Text] [Related]
20. Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.
Lastres-Becker I; Gómez M; De Miguel R; Ramos JA; Fernández-Ruiz J
Neurotox Res; 2002; 4(7-8):601-608. PubMed ID: 12709298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
